RGEN stock forecast
Our latest prediction for Repligen Corp.'s stock price was made on the Feb. 26, 2020 when the stock price was at 85.16$.
In the short term (2weeks), RGEN's stock price should underperform the market by -0.33%. During that period the price should oscillate between -6.31% and +8.27%.
In the medium term (3months), RGEN's stock price should underperform the market by -0.29%. During that period the price should oscillate between -19.82% and +17.40%.Get email alerts
Create a solid portfolio with RGEN
About Repligen Corp.
Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
At the moment the company generates 286M USD in revenues.
On its last earning announcement, the company reported a profit of 0.45$ per share.
The book value per share is 13.67$
Three months stock forecastFeb. 26, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|